ABSTRACT
Organ availability limits kidney transplantation, the best treatment for end-stage kidney disease. Deceased donor acceptance criteria have been relaxed to include older donors with higher risk of inferior posttransplant outcomes. More granular prediction models, based on deeper resolution organ assessment and understanding of damage processes, could substantially improve donor organ allocation and reduce graft dysfunction risk. Here, we profiled pre-implantation kidney biopsy proteomes from 185 deceased donors by high-resolution mass spectrometry and used machine learning to integrate and model these data, and donor and recipient clinical metadata to predict outcome. Our analysis and orthogonal validation on an independent cohort revealed 136 proteins predictive of outcome, 124 proteins of which showed donor-age modulated predictive effects. Observed associations with inflammatory, catabolic, lipid metabolism and apoptotic pathways may predispose donor kidneys to suboptimal posttransplant outcomes. Our work shows that integrating kidney proteome information with clinical metadata enhances the resolution of donor kidney quality stratification, and the highlighted biological mechanisms open new research directions in developing interventions during donor management or preservation to improve kidney transplantation outcome.
TRANSLATIONAL STATEMENT We profiled the proteome of pre-implantation biopsies selected from donor kidneys on the basis of paired 12-month graft function. Our data reveal a signature of proteins which contribute to transplant outcomes, many of these show different strengths of association dependent on donor age. The biological themes of the identified candidates reinforce immuno-metabolic and catabolic mechanisms as potential contributors to donor kidney susceptibility that may reduce graft recovery after transplantation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by NHS Blood and Transplant WP15-07 awarded to MK & RJP. SF was supported by Kidney Research UK, grant reference KS_RP_002_20210111 awarded to MK. PDC was supported by a Chinese Academy of Medical Sciences 2018-I2M-2-002 awarded to BMK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NHS Health Authority, National Research Ethics Service, gave ethical approval for IRAS project ID: 87824, Quality in Organ Donation (QUOD) (NW/18/0187), sponsored by University of Oxford
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 67 partner repository with the dataset identifier PXD033428. All other data produced are contained in the manuscript or supplemental materials.
